Fig. 1: PTENα remains active in PTEN-mutant cancers.

a Cartoons of structures of PTEN and PTENα. Domains that are contained by PTEN and PTENα are shown in the simplified drawing, respectively. Stop gained mutations include all the nonsense or frameshift mutations terminated after H¹⁸⁵ (last amino acid of phosphatase tensin-type domain of PTEN). Phosphatase-inactive mutations are from the UniProt database. Some of the two kinds of mutations are indicated in the graph. b Survival curve of uterine corpus endometrial carcinoma (UCEC) patients with PTEN mutations (Stop gained mutations, n = 117; Phosphatase-inactive mutations, n = 51, *P = 0.0377). Clinical data were acquired from the TCGA database. c GSEA of RNA-seq data of UCEC patients with matched diagnosis age (40–60 years), aneuploidy score (<3), and neoplasm histologic grade (G3). The data were acquired from the TCGA database. ES is an abbreviation of Enrichment Score, and NES represents Normalized Enrichment Score. d Expression levels of immune surveillance-related genes in uterine corpus endometrial carcinoma (UCEC) patients with indicated PTEN mutations (Stop gained mutations, n = 117; Phosphatase-inactive mutations, n = 51, mean ± s.e.m., *P (PTPRC) = 0.0400, *P (CD4) = 0.0498, **P = 0.0022). e and f Immunoblot analysis of expression of GFP-tagged PTEN and PTENα carrying indicated mutations in HEK293T cells treated with 100 μg/ml CHX for indicated hours. An anti-GFP antibody was used. Gray values of PTEN and PTENα relative to GAPDH were determined, using for the line chart. Statistical significance was assessed by Log-rank (Mantel–Cox) test (b) or two-tailed unpaired Student’s t test without multiple comparisons test (d). Data are representative of two (e and f) independent experiments with similar results. Source data are provided as a Source Data file. See also Supplementary Fig. 1.